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Background. There are limited epidemiological studies evaluating the effect of age at onset on disease features in vitiligo.Objectives.
To identify factors associated with adult onset vitiligo in comparison with childhood onset vitiligo. Patients and Methods. We
retrospectively collected medical records of 191 patients. Such records included clinical examination, personal and familial medical
history, laboratory evaluations, concomitant vitiligo treatment and drug assumption. Results. 123 patients with a disease onset
after the age of 40 (adult onset vitiligo) were compared with 68 patients who developed vitiligo before the age of 12 (childhood
onset vitiligo). Multivariate analysis revealed that personal history of thyroid diseases (𝑃 = 0.04; OR 0.4), stress at onset
(𝑃 = 0.002; OR = 0.34), personal history of autoimmune thyroid disease (ATD) (𝑃 = 0.003; OR = 0.23), and thyroid nodules
(𝑃 = 0.001; OR 0.90) were independently associated with adult onset vitiligo, whereas family history of dermatological diseases
(𝑃 = 0.003; OR = 2.87) and Koebner phenomenon (𝑃 < 0.001; OR = 4.73) with childhood onset vitiligo. Moreover, in the
adult onset group, concomitant thyroid disease preceded vitiligo in a statistically significant number of patients (𝑃 = 0.014).
Conclusions. Childhood onset and adult onset vitiligo have different clinical features. In particular, ATD and thyroid nodules
were significantly associated with adult onset vitiligo, suggesting that a thyroid screening should be recommended in this group of
patients.
1. Introduction
Vitiligo is a chronic acquired pigmentary skin disorder, clini-
cally characterized by well-defined asymptomatic white mac-
ules, which are the result of a loss of functionalmelanocytes in
the epidermis. It is considered the most common pigmentary
disorder, affecting 0.1–2% of the world population, with no
sexual or racial preference [1].
Vitiligo can appear at any age, but it has been most
frequently observed in the first two decades [2].
In particular, it tends to appear before the age of 10 in
about 25% of the patients [3, 4]. However, a disease onset
during adulthood is a common condition as well [5], even if
to date only few studies [6, 7] have described the clinic profile
of adult onset vitiligo.
We herein present the results of a retrospective observa-
tional study comparing the clinical characteristics of adult
and childhood onset vitiligo through univariate analysis and
multivariate conditional logistic regression.
2. Patients and Methods
We retrospectively collected medical records of 500 consecu-
tive patients diagnosed with vitiligo attending the Florence
University specialized vitiligo outpatient service between
June 2010 and June 2013. Patients with vitiligo arisen between
the ages of 12 and 40 years were excluded from the study.
The remaining 191 patients were divided into two groups,
according to the age at onset of the disease: the adult onset
group including 123 patients with a disease onset after the age
of 40 and the childhood onset group including 68 patients,
both children and adults, having a disease onset before the
age of 12 years.
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The study design was conducted according to the Dec-
laration of Helsinki principles and informed consent was
obtained from each patient.
2.1. Medical Assessment. Medical records included clinical
examination, personal and familial medical history, labo-
ratory evaluations, and concomitant vitiligo treatment and
drug assumption.
Medical assessment was performed using a modified
VETF form [8, 9]. This evaluation individually assesses four
body regions (head and neck, trunk, upper extremities, and
lower extremities), examined both under natural light and
underWood lamp, for the extent of depigmentation (affected
body surface percentage scored 0–100%), stage of disease
(staging), scored 0–4 (normal pigmentation, incomplete
depigmentation, complete depigmentation, complete depig-
mentation plus partial leukotrichia, and complete depigmen-
tation plus complete leukotrichia), and disease progression
(spreading), scored−1 to +1 (ongoing subclinical repigmenta-
tion, similar limits, and ongoing subclinical depigmentation).
A total score for the aforementioned parameters was calcu-
lated with values ranging from 0 to 16 for staging and −4 to
+4 for spreading.
The following demographic and clinical information was
taken into consideration: sex, age, age at onset of the disease,
phototype, Koebner phenomenon, presence of Sutton naevi,
personal history of premature hair graying (more than 50%
of white hair before the age of 40 years), emotional stress
as a triggering factor, previous episodes of repigmentation,
inflammation/pruritus of the macules, and modality of onset
of vitiligo.
We also evaluated personal and familial history of auto-
immune diseases (pernicious anemia, Addison’s disease, sys-
temic lupus erythematosus, inflammatory bowel disease, alo-
pecia areata, multiple sclerosis, myasthenia gravis, rheuma-
toid arthritis, scleroderma, Sjogren’s syndrome, coeliac dis-
ease), thyroid disorders (in general and specifically autoim-
mune thyroid disorders (ATD) or nodules), cardiovascular,
psychiatric, and neurological diseases, diabetes, hyperten-
sion, and dermatological diseases (in general and specifically
psoriasis, atopic dermatitis, and melanoma). Familial history
of vitiligo was also investigated.
Laboratory examinations included serum levels of tri-
iodothyronine (T3) and thyroxine (T4) thyroid stimulating
hormone (TSH) and the following autoantibody titers: anti-
thyroglobulin (anti-TG), anti-thyroperoxidase (anti-TPO),
anti-TSH receptor (anti-TSHR), anti-parietal cell antibody
(APCA), anti-smoothmuscle antibody (ASMA), anti-nuclear
antibody (ANA), and extractable nuclear antibody (ENA).
2.2. Statistical Analysis. Characteristics of the study pop-
ulation were described using mean, standard deviations,
frequencies, and percentages. In order to recognize factors
associated with an age of onset >40 years and an age of onset
<12 years, comparisons between groups were conducted by
univariate and multivariate conditional logistic regression.
Every possible potential predictor of the above-mentioned
age of onset was firstly assessed individually, using the chi
square/Fisher tests for categorical data and Student’s 𝑡-test
for quantitative data in a univariate analysis. The odds ratios
(OR), the corresponding 95% confidence intervals (CIs), and
𝑃 values were computed. Secondarily, every predictor was
assessed using multivariate analysis, with odds ratios and
associated 95% confidence intervals.
All 𝑃 values < 0.05 were considered to be statistically
significant. Statistical analyses were performed using the
SPSS 15.0 forWindows program (Statistical Package for Social
Science, SPSS Inc., Chicago, IL, USA).
3. Results
Patient demographics and clinical characteristics are shown
in Table 1.
Results of the univariate analysis for patient characteris-
tics in the adult onset group versus childhood onset disease
revealed that phototype III (OR 0.49; 𝑃 = 0.021), personal
history of hypertension (OR 0.8; 𝑃 < 0.001), head and neck
involvement at disease onset (𝑃 = 0.007), and stress as an
onset factor (OR 0.29; 𝑃 < 0.001) were all positively asso-
ciated with adult onset vitiligo. Moreover this group showed
a significantly higher prevalence of thyroid disease (OR 0.27;
𝑃 < 0.001), ATD (OR 0.22; 𝑃 = 0.02), and thyroid nodules
(OR 0.9; 𝑃 = 0.002).
On the contrary, family history of dermatological condi-
tions (OR 2.615; 𝑃 = 0.002), family history of autoimmune
diseases (OR 3.96; 𝑃 = 0.020), phototype II (OR 2.02;
𝑃 = 0.021), initial localization of the disease involving upper
extremities (𝑃 = 0.009), and the presence of Koebner pheno-
menon (OR 3.00; 𝑃 < 0.001) were all positively associated
with childhood onset. Complete results of the univariate
statistical analysis are listed in Table 1.
The results of the multivariate analysis pointed out that
a family history of dermatological diseases (𝑃 = 0.003, OR
2.87) and Koebner phenomenon (𝑃 < 0.001, OR 4.73) were
independently associated with an age of onset of vitiligo <12
years (Table 2). In contrast, stress at onset (𝑃 = 0.002, OR
0.34), personal history of thyroid diseases (𝑃 = 0.04, OR 0.4),
ATD (𝑃 = 0.003, OR 0.23), and thyroid nodules (𝑃 = 0.001,
OR 0.90) were independently associated with vitiligo age of
onset >40 years.
In light of this data, we performed a further analysis in
our patients affected by both vitiligo and thyroid disease, in
order to evaluate whether or not the onset of vitiligo appeared
prior to thyroid disease. According to our results, in the adult
onset group, thyroid disease preceded vitiligo in a statistically
significant number of patients (𝑃 = 0.014). However no
statistical association was found when we performed this
analysis considering ATD and thyroid nodules separately.
4. Discussion
Until now, there is a lack of information about the clinical
and epidemiologic profile of adult onset vitiligo and only
few studies have compared its characteristics with early onset
disease [10–12]. The purpose of our study was to describe the
effect of age at onset on disease features.
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Table 1: Patients characteristics and complete results of the univariate analysis.
Parameter (∗) Age of onset <12 years Age of onset >40 years 𝑃 OR
Mean age at onset 7 years (range 0–12) 50.25 years (range 40–83)
Mean age at time of consultation 19.5 years (range 3–69) 56.3 years (range 41–85)
Mean duration of the disease 12.2 years (range 0.3–62) 6.2 years (range 0.2–30)
Sex
Female 34 (50.0%) 68 (55.2%) 0.438 1.236
Male 34 (50.0%) 55 (44.8%)
Type
Segmental 4 (5.9%) 4 (3.3%) 0.463 0.552
Nonsegmental 62 (91.2%) 116 (96.6%) 0.173 2.806
Unclassified 2 (2.9%) 0 0.130 0.355
Family history
Vitiligo 22 (32.3%) 25 (24.3%) 0.247 0.670
Psoriasis 17 (25.0%) 15 (14.5%) 0.087 0.511
Melanoma 4 (5.8%) 6 (5.8%) 0.988 0.990
Dermatological 36 (52.9%) 37 (34.2%) 0.002 2.615
Thyroid disease 23 (33.8%) 29 (26.8%) 0.324 0.718
Cardiovascular disease 9 (13.2%) 10 (10.0%) 0.516 0.728
Type I diabetes 1 (1.4%) 5 (4.9%) 0.231 3.490
Type II diabetes 12 (17.6%) 16 (15.8%) 0.921 0.878
Autoimmune disease 8 (11.7%) 4 (4.0%) 0.020 3.96
Hypertension 14 (20.5%) 13 (12.8%) 0.179 0.570
Neurologic disease 0 (0.0%) 1 (1.0%) 0.406 0.590
Personal history of
Thyroid disease 13 (19.1%) 40 (37.7%) <0.001 0.27
ATD 7 (10.6%) 27 (25.0%) 0.020 0.22
Thyroid nodules 0% 13 (12.0%) 0.002 0.90
Cardiovascular disease 3 (4.4%) 5 (5.0%) 1.000 1.152
Autoimmune disease 3 (4.4%) 7 (7.0%) 0.742 1.649
Type I diabetes 0 (0.0%) 2 (2.0%) 0.515 0.590
Type II diabetes 0 (0.0%) 3 (3.0%) 0.273 0.588
Hypertension 0 (0.0%) 18 (18.1%) <0.001 0.8
Psychiatric disease 0 (0.0%) 3 (3.0%) 0.273 0.588
Neurologic disease 1 (1.5%) 2 (2.0%) 1.000 1.367
Phototype
I 1 (1.5%) 0 (0.0%) 0.364 0.360
II 36 (52.9%) 44 (36.9%) 0.034 0.521
III 28 (41.2%) 68 (62.4%) 0.036 1.905
IV 2 (2.9%) 7 (5.9%) 0.491 2.063
V 1 (1.5%) 0 (0.0%) 0.364 0.360
Previous episode of repigmentation
Spontaneous 4 (5.9%) 8 (8.0%) 0.764 1.376
Drug induced 27 (39.7%) 33 (32.9%) 0.349 0.737
Photoexposition 9 (13.2%) 9 (9.0%) 0.372 0.641
Type of Onset
Sudden 30 (44.1%) 57 (48.7%) 0.618 1.165
Progressive 35 (51.5%) 62 (52.1%) 0.934 1.026
Leucotrichia 16 (23.5%) 35 (36.0%) 0.086 1.835
Sutton 8 (11.7%) 7 (8.9%) 0.580 0.739
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Table 1: Continued.
Parameter (∗) Age of onset <12 years Age of onset >40 years 𝑃 OR
Koebner 42 (61.7%) 43 (43.8%) <0.001 0.484
Stress as onset factor 29 (42.6%) 67 (65.0%) <0.001 2.503
∗Continuous variables such as age, age of onset, and vitiligo duration are reported as mean ± SD and expressed in years. For every other parameter evaluated,
we report the number and the percentage of patients positive or negative for that parameter.
Table 2: Significant results of the multivariate conditional logistic
regression.
Parameter 𝑃 OR
Family history of dermatological disease 0.003 2.87
Personal thyroid diseases 0.04 0.4
Koebner <0.001 4.73
Stress as onset factor 0.002 0.34
Personal ATD 0.003 0.23
Personal thyroid nodules 0.001 0.90
In our study, both sexes were equally affected and we did
not find any significant difference in sex ratio (M : F, 1 : 1)
between adult and childhood onset vitiligo. This result is
in accordance with two previous papers [3, 13]. However, a
female preponderance has been reported in childhood onset,
compared with adult onset, vitiligo [4, 14]. Other studies
[11, 12] comparing disease characteristics in childhood and
later onset vitiligo (disease onset after the age of 12) reported
a female preponderance in both groups.
The role of stress as an onset factor in vitiligo has been
widely investigated, both in adults and in children [15, 16].
In our study patients with adult onset vitiligo recalled a
stressful event with significantly higher frequency compared
to thosewith childhoodonset.This result is in agreementwith
the above-mentioned studies, regarding childhood and later
onset vitiligo [11, 12]. However, according to Ezzedine et al.
[11] patients with childhood onset vitiligo might be less able
to recall such an event when seen first in adulthood, so a recall
bias could be responsible for this difference.
Among the other significant results, we found a signifi-
cantly higher prevalence of thyroid disease, ATD, and thyroid
nodules in adult onset vitiligo patients. With regard to ATD,
the reported diagnosis was confirmed by positive serum anti-
TPO, anti-TG, anti-TSHR, and suggestive ultrasonography.
The association between ATD and vitiligo has been widely
explored in children [17]. On the contrary little is known
about this relationship in adult onset vitiligo. As reported in a
recent systemic review [18], patients with vitiligo show a 2.5-
fold higher risk of developing ATD compared with patients
without vitiligo.The risk of developingATDseems to increase
with age and this is in accordance with the assumption of
the increase in prevalence of autoimmunity with age [19].
This could explain the statistical association assessed by our
study, since mean age in adult onset group is higher than in
the childhood onset one. Our results are also in agreement
with the paper of Nicolaidou et al. [12], claiming that the
risk of developing ATD was significantly lower when vitiligo
appeared during childhood.
We also found an association between adult onset disease
and thyroid nodules which, to our knowledge, has never been
studied so far.This relationship could be due to the higher age
of this group (56.3 yr versus 19.5 yr), which is considered an
important risk factor for thyroid nodules [20].
Analyzing the age at onset of vitiligo compared with
thyroid disease in patients affected by both diseases we found
that, in the adult onset group, thyroid disease tends to precede
vitiligo in a significant number of patients. According to
recent studies [21, 22] ATD is associated with an increased
systemic oxidative stress, which has been shown to play a
major role in the pathogenesis of vitiligo [23]. In our analysis
the relationship between adult onset vitiligo and previous
thyroid disease was confirmed only when thyroid disease was
considered on the whole, since statistical significance was lost
when ATD and nodules were considered separately. However
it should be considered that 68% of the cases of thyroid
diseases we considered in our analysis were actually ATD,
so it is possible that the loss of significance considering ATD
alone could be related to the smaller number of patients.
Our analysis also revealed a significantly higher preva-
lence of Koebner phenomenon in the childhood onset group
(𝑃 < 0.001), which had not been observed in other studies. A
possible explanation for these figures could be that children
are more likely to undergo skin traumas while playing and
therefore to develop koebnerization of the skin. However our
childhood onset group also included adults so other factors
might be involved in this phenomenon.
Patients with childhood onset vitiligo were also more
likely to have a positive history of dermatological diseases in
their family, but when dermatological diseases were analyzed
individually, no significant association between childhood
vitiligo and a family history of vitiligo,melanoma, or psoriasis
was found. Personal and familial history of atopic dermatitis
were not associated with childhood onset vitiligo, in contrast
with Ezzedine et al. [11]. This difference could be due to a
recall error, since atopic dermatitis usually develops in the
first year of life, and the majority of affected individuals have
resolution of disease by adulthood [24].
The limitations of the study include possible recall bias,
especially in patients whose disease startedmany years before
presentation to our clinic.
5. Conclusions
In conclusion, upon multivariate conditional regression,
our study shows that adult and childhood onset vitiligo
have different clinical features. Childhood onset vitiligo is
significantly associated with family history of dermatological
conditions and Koebner phenomenon, whereas adult onset
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vitiligo is associated with stress as an onset factor, thyroid
disease, ATD, and thyroid nodules. Those differences must
be kept in due consideration in order to suggest appropriate
screening programs and follow-up; thyroid screening in
particular should be suggested to all patients with vitiligo,
but its importance is even stronger in adult onset vitiligo,
since the risk of developing thyroid disease is higher in these
patients.
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